


# Thoracic Disease-Oriented Team

---

Clinical Research Treatment Flowchart

ADVANCED/METASTATIC

 Open to Accrual

 Low Accruing

 Pending Activation

ALK

1L

2L

UCI 21-241(Nuvalent)  
NVL-655 + ALK inhibitor

Mechanism: TKI Inhibitor  
Coord: Keagan Buttigieg  
Accrual: 6/10

ADVANCED/METASTATIC

Exon 18

Open to Accrual

Low Accruing

Pending Activation

Exon 19 del or L858R

1L

UCI 20-119 (Janssen)  
JNJ-6118637 + Lazertinib

Mechanism: TKI  
Coord: Richard Chang  
Accrual: 10/13

UCI 22-217(Janssen)  
Amivantamb + Lazertinib w/  
or without Carbo +  
Pemetrexed

Mechanism: Antibody drug  
w/ TKI and Chemo  
Coord: Celest Ramirez  
Accrual: 2/5

2L

UCI 23-95 (HARMONi)  
Randomized Double Blind: AK112/Placebo + Pem +  
Carbo

Mechanism: Novel PD-1/VEGF bispecific antibody w/  
Chemo  
Coord: Celest Ramirez  
Accrual: 0/10

UCI 22-121 (Jintsbio)  
JIN-A02 Monotherapy

Mechanism: TKI  
Coord: Richard Chang  
Accrual: 0/7

## Exon 20

## Exon 21

1L

UCI 22-217(Janssen)  
Amivantamb + Lazertinib w/ or without Carbo + Pemetrexed

Mechanism: Antibody drug w/ TKI and Chemo  
 Coord: Celest Ramirez  
 Accrual: 2/5

UCI 22-217(Janssen)  
Amivantamb + Lazertinib w/ or  
without Carbo + Pemetrexed


Mechanism: Antibody drug w/ TKI  
 and Chemo  
 Coord: Celest Ramirez  
 Accrual: 2/5

2L

UCI 23-95 (HARMONi)  
Randomized Double Blind: AK112/Placebo + Pem + Carbo

Mechanism: Novel PD-1/VEGF bispecific antibody w/ Chemo  
 Coord: Celest Ramirez  
 Accrual: 1/5

## Stage 1A / Adjuvant

 Open to Accrual Low Accruing Pending Activation

UCI 22-59 (ADAURA)  
Randomized: Osimertinib or Placebo

Mechanism: TKI  
Coord: Jenny Choe  
Accrual: 0/10

## cMET and EGFR

1L

2L

UCI 20-195 (MCLA-129)

Mechanism: Antibody Drug  
Coord: Cynthia Gonzalez  
Accrual: 12/20

UCI 21-105 (MEXMET)  
REGN5093-M114

Mechanism: Antibody Drug  
Conjugate(ADC)  
Coord: Richard Chang  
Accrual: 0/5

## ADVANCED/METASTATIC

1L

UCI 23-66 (Boehringer Ingelheim)  
BI-1810631 Monotherapy

Mechanism: TKI  
Cord: Keagan Buttigieg  
Accrual: 0/5

2L

Exon 19

Exon 20

UCI 21-234 (AstraZeneca)

Randomized: Arm 1: T-DXD(Trastuzumab Deruxtecan) or  
Arm 2: Cisplatin or Carbo + Pemetrexed + Pembrolizumab

\*Treatment Naïve for palliative intent systemic therapy in  
locally advanced or metastatic disease.

\*Documented Her2 Exon 19 or 20 mutation

\*Tumor sample must be available for central testing from  
fresh or archival.

\*No Slot Required prior to consenting if mutation of HER2  
is available.

Accrual: 1/10

## ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation

## KRAS G12C

1L

UCI 22-30 (D3S-001-100) D3 Bio

Mechanism: TKI  
Coord: Richard Chang  
Accrual: 0/3

2L

UCI 22-88 (RMC-6291 Revolution Med)

Mechanism: TKI  
Coord: Richard Chang  
Accrual: 3/25

UCI 21-53 (Loxo Oncology, Inc. LOXO-RAS-20001)

Mechanism: TKI  
Coord: Jenny Choe  
Accrual: 6/8

UCI 20-141 (Genentech, Inc)

Mechanism: TKI  
Coord: Richard Chang  
Accrual: 3/20

UCI 18-78 (Mirati MRTX-849)

Mechanism: TKI  
Coord: Celest Ramirez  
24/40

G12A, G12D, G12R, G12S,  
G12VUCI 22-87 (RMC-6236 Revolution Med)

Mechanism: TKI  
Coordinator: Oliver Quines  
Accrual: 6/20



## ADVANCED/METASTATIC

### Immunotherapy + Radiation

NRG-LU007

Treatment: (Randomized) Group 1:  
Atezolizumab Alone. Group 2:  
Atezolizumab + Radiation

Mechanism: Immunotherapy +  
 Radiation

Coord: Richard Chang  
 Accrual: 1/5

 Open to Accrual

 Low Accruing

 Pending Activation

UCI 23-178

Treatment: BL-B01D1 IV  
 Mechanism: IP binding to EGFR/HER3,  
 antibody fragments of IP bind to  
 EGFR/HER3, Fc segment of (ADCC)  
 Coord: TBA  
 Accrual: 0/10

ADVANCED/METASTATIC

NTRK 1-3

Open to Accrual

Low Accruing

Pending Activation

1L

2L

UCI 16-79 (TPX-0005)

Mechanism: TKI

Coord: Stephanie Fernandez

Accrual: 16/27

ADVANCED/METASTATIC

Open to Accrual

Low Accruing



Pending Activation

All Comers

3L

---

ADVANCED/METASTATIC

 Open to Accrual Low Accruing Pending Activation

ROR2

1L

2L

UCI 21-161 (BA3021 /BioAtla)  
BA3021 alone an in comb w/ Nivolumab

Mechanism: Antibody drug conjugate  
Coord: Celest Ramirez  
Accrual: 0/5

ADVANCED/METASTATIC

 Open to Accrual Low Accruing Pending Activation

ROS1

1L

2L


UCI 21-47 ( NVL-520 Nuvalent)

Mechanism: TKI  
Coord: Keagan Buttigieg  
Accrual: 6/10

## Database & Repository

UCI 21-238: Database & Repository of  
Asian female never smokers w/ low dose  
CT scan Screening Study


Mechanism: D  
Coord: TBD  
Accrual: 0/100

 Open to Accrual

 Low Accruing

 Pending Activation

## Advanced / Metastatic

 Open to Accrual

 Low Accruing

 Pending Activation

1L

2L

UCI 23-148: CJRB-01 (oral) +  
Pembrolizumab

Mechanism: Live  
biotherapeutic product  
containing a novel strain  
belonging in the species  
*Leuconostoc mesenteroides*  
(*L. mesenteroides* +  
*Pembrolizumab*)  
Coord: TBD  
Accrual: 0/6





UCI 21-233: Mecbotamab  
vedotin (BA3011) &

Nivolumab

Mechanism: Immunotherapy

Coord: Jenny Choe

Accrual: 1/10